转自：新华财经 编者按：创新联合体是推动创新链深度融合、突破产业关键核心技术、提升企业及产业核心竞争力的重要机制，既深度契合现阶段技术创新"跨产业、多领 域交叉"的特征，更能显著提升重大研究成果产出效率与创新技术商业化转化效能。近年来，苏州工业园区以关键核心技术攻关重大任务为牵引，引导建设 了一批"利益融合、要素融通、能力融汇"的创新联合体，为突破重点产业发展瓶颈提供有力支撑。 在苏州工业园区（以下简称"园区"），一种生态融合型创新联合体正持续激发"化合反应"，推动科技创新与产业创新深度融合，加速高端医疗器械技术从实 验室走向生产线。作为苏州生物医药领域首个生态融合型创新联合体，苏州市介入医疗技术创新联合体由沛嘉医疗科技（苏州）有限公司（以下简称"沛嘉 医疗"）牵头组建，构建形成"龙头企业引领+上下游创新型企业参与+科研机构联合攻关+孵化器培育+投资基金支持"的运行模式，着力打造集技术攻关、平 台建设、企业孵化、成果转化、产业培育、人才引进与临床医学服务为一体的产业创新生态，实现空间上集聚、创新上集成、产业上协同，孵化出众多创新 产品、高性能材料与优质项目，助推区域高端医疗器械产业高质量发展。 空间上集聚：整 ...

Core Insights - The integration of technological innovation and industrial innovation is essential for achieving high-quality economic development, transforming from "strong technology" to "strong industry" and ultimately to "strong economy" [1] - Suzhou Industrial Park aims to be a world-class high-tech park through open innovation, leveraging its strengths as a national economic development zone and high-tech zone to lead in the integration of technology and industry [1] Group 1: Industrial Innovation Driving Technological Innovation - Industrial innovation provides direction for the realization of technological innovation value, serving as a key link in converting technological achievements into economic growth [2] - Suzhou Industrial Park focuses on addressing issues such as lack of emphasis on key research areas and insufficient collaboration in industrial chain efforts, driving technological breakthroughs based on industrial demand [2] Group 2: Targeted Technological Research and Development - The park emphasizes a shift from a "one-size-fits-all" approach to a more precise, demand-driven research strategy, enhancing the relevance of technological breakthroughs to market needs [4] - Collaboration between enterprises and universities is crucial for aligning technological research with industry pain points, ensuring that innovation is market-oriented [4][6] Group 3: Success Stories in Innovation - Suzhou Nano City showcases successful collaborations, such as the partnership between Sujing Group and Suzhou Nano Technology Co., which led to the development of high-quality microspheres for particle detection [5] - The park has seen significant growth in its nano industry, with over 1,400 companies and a projected output value exceeding 170 billion yuan by 2024 [6] Group 4: Collaborative Innovation Ecosystem - The establishment of innovation consortia led by key enterprises facilitates multi-field collaborative innovation, enhancing the efficiency of technology commercialization [7][9] - The park has approved 26 innovation consortia, which have collectively increased patent authorizations by 50.4% year-on-year, demonstrating the effectiveness of collaborative innovation [9] Group 5: Talent and Platform Development - The park has initiated programs to attract high-level talent, supporting over 2,700 projects and contributing to the establishment of 60% of the park's listed companies [10] - A robust public service platform has been developed to provide comprehensive support for enterprises, including technology transfer and commercialization services [11] Group 6: Future Directions - The park aims to further enhance its policy framework and mechanisms to promote the deep integration of technological and industrial innovation, accelerating the development of new productive forces [12]

Core Viewpoint - The article highlights the growing significance of heart valve diseases in the context of an aging population, with Beijing Bairen Medical Technology Co., Ltd. emerging as a key player in the domestic market for artificial heart valves, breaking the monopoly of foreign companies and achieving self-sufficiency in core technologies [2][3]. Company Overview - Bairen Medical is the only A-share listed company in the structural heart disease sector in China, focusing on original research and innovation for over 20 years [2]. - The company has developed a bioprosthetic valve using bovine pericardium, which surpasses imported products in anti-calcification performance and durability, addressing the long-standing reliance on imported valves for Chinese patients [2][3]. Innovation and R&D - The development of bioprosthetic valves requires advanced animal tissue engineering and chemical modification techniques, with Bairen Medical investing significantly in R&D, with a budget of 151 million yuan in 2024, a 53.26% increase year-on-year, representing 30.17% of its revenue [4]. - The company has received approval for 21 Class III medical device products, with 10 filling domestic gaps, and has launched 11 interventional products covering the entire lifecycle of heart valve treatment [4]. Market Performance - In 2024, Bairen Medical achieved a revenue of 502 million yuan, a 35.41% increase, and a net profit of 146 million yuan, a 27.02% increase, with all three business segments showing growth [5]. - The heart valve replacement and repair segment saw a revenue increase of 64.28%, with artificial biological heart valves growing by 75.06% [5]. International Expansion - Bairen Medical is entering international markets, with over ten products registered in Indonesia and plans to expand to Germany, Singapore, and Japan [6]. - The company acquired a U.S. firm, Tianqiong Innovation, to enhance its capabilities in ePTFE materials, addressing the long-standing issue of dependence on imports [6]. Regulatory and Systemic Innovations - The company aims to accelerate the market entry of high-end medical devices through regulatory innovations, advocating for transparent review standards and improved communication mechanisms in the registration process [6].